A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors

A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors

<h4>Purpose</h4> Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib and was applied retrospe...

Full description

Bibliographic Details
Main Authors: Steen Knudsen, Anker Hansen, Marie Foegh, Steen Petersen, Hana Mekonnen, Lin Jia, Preeti Shah, Victoria Martin, Gregory Frykman, Roberto Pili
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468037/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468037/?tool=EBI

Similar Items